CD8A and glioblastoma: Likewise, in the CT26 colon carcinoma (52) and glioblastoma (64) mouse models, co-blockade of TIGIT and PD-1/PD-L1 pathway synergistically decreased tumor burden and improved survival by increasing IFN-γ+ CD8+ TILs (52).